• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Whole-Genome Analysis Surveillance of Influenza A Virus Resistance to Polymerase Complex Inhibitors in Eastern Spain from 2016 to 2019.2016 年至 2019 年西班牙东部地区甲型流感病毒对聚合酶复合体抑制剂耐药性的全基因组分析监测。
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.02718-20.
2
Next-Generation Sequencing: An Eye-Opener for the Surveillance of Antiviral Resistance in Influenza.下一代测序：监测流感病毒耐药性的新视角。
Trends Biotechnol. 2020 Apr;38(4):360-367. doi: 10.1016/j.tibtech.2019.09.009. Epub 2019 Dec 4.
3
Antiviral Susceptibilities of Distinct Lineages of Influenza C and D Viruses.流感 C 型和 D 型病毒不同谱系的抗病毒敏感性。
Viruses. 2023 Jan 15;15(1):244. doi: 10.3390/v15010244.
4
Incidence of antiviral drug resistance markers among human influenza A viruses in the Eastern Mediterranean Region, 2005-2016.2005-2016 年在东地中海地区流行的人甲型流感病毒的抗病毒药物耐药性标志物的发生率。
Infect Genet Evol. 2019 Jan;67:60-66. doi: 10.1016/j.meegid.2018.10.023. Epub 2018 Oct 30.
5
Detection of baloxavir resistant influenza A viruses using next generation sequencing and pyrosequencing methods.使用下一代测序和焦磷酸测序方法检测耐巴洛沙韦的流感 A 病毒。
Antiviral Res. 2020 Oct;182:104906. doi: 10.1016/j.antiviral.2020.104906. Epub 2020 Aug 14.
6
Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.全球 2017-2018 年人类流感病毒对神经氨酸酶抑制剂和帽依赖性内切酶抑制剂巴洛沙韦耐药性的最新情况。
Antiviral Res. 2020 Mar;175:104718. doi: 10.1016/j.antiviral.2020.104718. Epub 2020 Jan 28.
7
Treatment-Emergent Influenza Virus Polymerase Acidic Substitutions Independent of Those at I38 Associated With Reduced Baloxavir Susceptibility and Virus Rebound in Trials of Baloxavir Marboxil.治疗后出现的流感病毒聚合酶酸性取代与 I38 无关，与巴洛沙韦马波昔韦降低敏感性和病毒反弹有关：巴洛沙韦马波昔韦临床试验结果
J Infect Dis. 2020 Aug 17;222(6):957-961. doi: 10.1093/infdis/jiaa164.
8
Antivirals targeting the polymerase complex of influenza viruses.抗流感病毒聚合酶复合物的药物。
Antiviral Res. 2019 Sep;169:104545. doi: 10.1016/j.antiviral.2019.104545. Epub 2019 Jun 25.
9
Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.从使用法匹拉韦前后的患者中分离出的流感病毒的抗病毒敏感性。
Antiviral Res. 2016 Aug;132:170-7. doi: 10.1016/j.antiviral.2016.06.007. Epub 2016 Jun 16.
10
Influenza virus polymerase inhibitors in clinical development.处于临床开发阶段的流感病毒聚合酶抑制剂。
Curr Opin Infect Dis. 2019 Apr;32(2):176-186. doi: 10.1097/QCO.0000000000000532.

引用本文的文献

1
Infection and tissue distribution of highly pathogenic avian influenza A type H5N1 (clade 2.3.4.4b) in red fox kits ().高致病性禽流感 A 型 H5N1（谱系 2.3.4.4b）在赤狐幼崽中的感染和组织分布（）。
Emerg Microbes Infect. 2023 Dec;12(2):2249554. doi: 10.1080/22221751.2023.2249554. Epub 2023 Aug 17.
2
Low prevalence of influenza A strains with resistance markers in Brazil during 2017-2019 seasons.2017-2019 年期间巴西流感 A 株耐药标志物的低流行率。
Front Public Health. 2022 Sep 14;10:944277. doi: 10.3389/fpubh.2022.944277. eCollection 2022.
3
Comprehensive Profiling of Mutations to Influenza Virus PB2 That Confer Resistance to the Cap-Binding Inhibitor Pimodivir.全面分析导致流感病毒 PB2 对帽结合抑制剂 Pimodivir 产生耐药性的突变。
Viruses. 2021 Jun 22;13(7):1196. doi: 10.3390/v13071196.

本文引用的文献

1
Comprehensive assessment of amino acid substitutions in the trimeric RNA polymerase complex of influenza A virus detected in clinical trials of baloxavir marboxil.全面评估在临床试验中检测到的甲型流感病毒三聚体 RNA 聚合酶复合物中的氨基酸取代。
Influenza Other Respir Viruses. 2021 May;15(3):389-395. doi: 10.1111/irv.12821. Epub 2020 Oct 24.
2
Fitness of influenza A and B viruses with reduced susceptibility to baloxavir: A mini-review.甲型和乙型流感病毒对巴洛沙韦的耐药性降低的适应性：小型综述。
Rev Med Virol. 2021 May;31(3):e2175. doi: 10.1002/rmv.2175. Epub 2020 Sep 25.
3
Influenza A(H1N1)pdm09 virus exhibiting reduced susceptibility to baloxavir due to a PA E23K substitution detected from a child without baloxavir treatment.甲型 H1N1pdm09 病毒对巴洛沙韦的敏感性降低，原因是从未接受巴洛沙韦治疗的儿童中检测到 PA E23K 取代。
Antiviral Res. 2020 Aug;180:104828. doi: 10.1016/j.antiviral.2020.104828. Epub 2020 Jun 20.
4
Treatment-Emergent Influenza Virus Polymerase Acidic Substitutions Independent of Those at I38 Associated With Reduced Baloxavir Susceptibility and Virus Rebound in Trials of Baloxavir Marboxil.治疗后出现的流感病毒聚合酶酸性取代与 I38 无关，与巴洛沙韦马波昔韦降低敏感性和病毒反弹有关：巴洛沙韦马波昔韦临床试验结果
J Infect Dis. 2020 Aug 17;222(6):957-961. doi: 10.1093/infdis/jiaa164.
5
Replicative Fitness of Seasonal Influenza A Viruses With Decreased Susceptibility to Baloxavir.对巴洛沙韦敏感性降低的季节性流感 A 病毒的复制适应性。
J Infect Dis. 2020 Jan 14;221(3):367-371. doi: 10.1093/infdis/jiz472.
6
Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019.2019 年 2 月，日本出现对巴洛沙韦耐药的甲型 H3N2 流感病毒的人际传播。
Emerg Infect Dis. 2019 Nov;25(11):2108-2111. doi: 10.3201/eid2511.190757. Epub 2019 Nov 17.
7
Baloxavir and Treatment-Emergent Resistance: Public Health Insights and Next Steps.巴洛沙韦与治疗中出现的耐药性：公共卫生见解及后续步骤
J Infect Dis. 2020 Jan 14;221(3):337-339. doi: 10.1093/infdis/jiz245.
8
Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza.治疗后出现对巴洛沙韦敏感性降低的流感变异病毒：对单纯性流感的临床和病毒学结局的影响。
J Infect Dis. 2020 Jan 14;221(3):346-355. doi: 10.1093/infdis/jiz244.
9
Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019.2019 年 1 月，日本从一名未接受过巴洛沙韦治疗的住院儿童中检出的具有 I38T 聚合酶酸性亚基取代、对巴洛沙韦敏感性降低的甲型 H3N2 流感病毒。
Euro Surveill. 2019 Mar;24(12). doi: 10.2807/1560-7917.ES.2019.24.12.1900170.
10
Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons.评估 2016/17 年和 2017/18 年美国流行的流感病毒对 baloxavir 的敏感性。
Euro Surveill. 2019 Jan;24(3). doi: 10.2807/1560-7917.ES.2019.24.3.1800666.

2016 年至 2019 年西班牙东部地区甲型流感病毒对聚合酶复合体抑制剂耐药性的全基因组分析监测。

Whole-Genome Analysis Surveillance of Influenza A Virus Resistance to Polymerase Complex Inhibitors in Eastern Spain from 2016 to 2019.

机构信息

Virology Laboratory, Genomics and Health Area, Centro Superior de Investigación en Salud Pública, FISABIO-Public Health, Generalitat Valenciana, Valencia, Spain.

Microbiology Service, Center of Biomedical Diagnostics, Hospital Clínic, Universitat de Barcelona, Institute of Global Health, Barcelona, Spain.

出版信息

Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.02718-20.

DOI:10.1128/AAC.02718-20
PMID:33782005
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8315920/
Abstract

Molecular surveillance by whole-genome sequencing was used to monitor the susceptibility of circulating influenza A viruses to three polymerase complex inhibitors. A total of 12 resistance substitutions were found among 285 genomes analyzed, but none were associated with high levels of resistance. Natural resistance to these influenza A antivirals is currently uncommon.

摘要

采用全基因组测序进行分子监测，以监测循环流感 A 病毒对三种聚合酶复合物抑制剂的敏感性。在分析的 285 个基因组中发现了总共 12 个耐药突变，但没有一个与高水平耐药相关。目前，这些流感 A 抗病毒药物的天然耐药性并不常见。